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We report three cases of Clostridium difficile pancolitis in adults with cystic fibrosis (CF) in whom the presenting symptoms were atypical. All
three required treatment with systemic steroids, in addition to oral vancomycin and metronidazole to achieve resolution of the colitis. This
experience suggests that C. difficile colitis should be considered in individuals with CF presenting with non-specific abdominal symptoms.
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A 20-year-old pancreatic insufficient CF male, FEV1 60%
predicted, presented with a one week history of fever and
vomiting. He had not opened his bowels for 4 days. He was
dehydrated, hypotensive, tachycardic and had a temperature of
39 °C. His abdomen was soft, the lower quadrants were mildly
tender and his bowel sounds were quiet. Abdominal X-ray
was not suggestive of distal intestinal obstruction syndrome
(DIOS) and the erect chest X-ray showed no free air under the
diaphragm. His WBC was 67×109/L (normal range 4–11×109)
and CRP 305 mg/L (normal range 0–10).
Prior to this episode he had required frequent intravenous
anti-pseudomonal antibiotics and a two month course of oral
steroids for treatment of recurrent right upper lobe consolida-
tion. He had a past history of gastro oesophageal reflux, liver
disease and CF related diabetes. His maintenance treatment☆ These cases have been presented aurally in the fellow's gastrointestinal
case presentations at the 2007 European Cystic Fibrosis Conference in Belek,
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doi:10.1016/j.jcf.2008.02.007included omeprazole, and azithromycin had recently been dis-
continued due to diarrhoea.
An abdominal CT (Fig. 1) showed pancolitis and an enlarged
appendix. He was transferred to the intensive therapy unit, fluid
resuscitated and given intravenous cefuroxime and metronida-
zole before undergoing a laparoscopic appendicectomy. The
appendix was inflamed but had not ruptured and there was no
evidence of an intra-peritoneal collection. Flexible sigmoido-
scopy showed pseudomembranous colitis and stool tissue-
culture cytotoxicity assay was positive for C. difficile toxin.
Intravenous cefuroxime was stopped and he was commenced
on oral vancomycin and oral prednisolone 40 mg od. He made
a rapid clinical improvement and 6 days later his CRP and
WBC had reduced to 12 and 13 respectively. Vancomycin was
prescribed for 10 days in total and the prednisolone was weaned
gradually to zero. Stool samples were negative for C. difficile
toxin on subsequent testing.
Two months later, during a further course of intravenous
anti-pseudomonal antibiotics stool samples were C. difficile
toxin positive again. Oral metronidazole was started and con-
tinued for the duration of the intravenous antibiotics. Sub-
sequent stool samples were negative and on this occasion he
remained clinically well.
To date, 1 year later, he has experienced no further
bowel problems despite two further courses of intravenousd by Elsevier B.V. All rights reserved.
Fig. 1. Case 1 C. difficile pancolitis. The wall of the large bowel is grossly
thickened with florid mucosal enhancement, low attenuation sub-mucosal
oedema and mesenteric injection. The white arrows show the oedematous large
bowel with i.v. contrast demarcating the ‘accordion sign,’ due to oedematous
infolded mucosa. The white arrowhead shows air trapped between the infolded
mucosa.
Fig. 2. Case 3. Abdominal X-ray with small gas collections throughout the large
bowel suggestive of faecal loading and a degree of small bowel obstruction
consistent with distal intestinal obstruction syndrome.
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exacerbations.
2. Case 2
A 34 year-old pancreatic insufficient CF male, FEV1 45%
predicted, presented with a 4 day history of colicky abdominal
pain and nausea. He had experienced one episode of diar-
rhoea but otherwise reported normal stools. He had a history of
gastro oesophageal reflux which was treated with omeprazole.
He was chronically infected with Pseudomonas aeruginosa
and Mycobacterium abscessus and was treated with long term
minocycline, clarithromycin, nebulised TOBI and subcutaneous
interferon gamma. In the previous year he had required one
14-day course of intravenous meropenem and colomycin, which
he completed three weeks prior to this admission.
On examination he was dehydrated, tachycardic, hypoten-
sive and had a temperature of 39 °C. There was no evidence of
pulmonary exacerbation. His abdomen was soft, moderately
distended and tender in the lower quadrants with quiet bowel
sounds. His CRP was 161 and WBC 12.1. Abdominal X-ray
suggested faecal loading in the large bowel with no small bowel
obstruction. An abdominal CT scan showed severe pancolitis,
flexible sigmoidoscopy confirmed pseudomembranous colitis
and his stool sample was positive for C. difficile cytotoxin.
He was treated with intravenous metronidazole, oral vanco-
mycin and intravenous fluids. However, his pain, fevers and
nausea failed to resolve and his CRP rose to 356. Intravenous
hydrocortisone 100 mg bd was added, following which his
clinical condition rapidly improved. His CRP reduced to 72
within 2 days of starting steroid treatment and his stool becameC. difficile cytotoxin negative after 5 days of antibiotic treat-
ment. He completed three weeks treatment with oral vanco-
mycin and metronidazole and weaned the oral prednisolone
to zero. He discontinued minocycline and clarithromycin
while an inpatient and these were recommenced following
completion of colitis treatment. To date he has remained
symptom free from a bowel perspective for eight months
despite requiring two further courses of intravenous antibiotics
to manage pulmonary exacerbations. During these he was
prescribed oral metronidazole cover and no C. difficile toxin
was detected.
3. Case 3
A 24-year-old CF male, FEV1 21% predicted, presented with
a 3 day history of severe abdominal pain. He had not opened his
bowels for 4 days. He had a past history of gastro oesophageal
reflux and type 2 respiratory failure requiring nasal ventilation.
His medications included azithromycin and esomeprazole.
He was haemodynamically stable and well hydrated but his
temperature was 39.4 °C. There was no evidence of pulmonary
exacerbation. His abdomen was soft but slightly distended with
moderate tenderness in the lower quadrants. Bowel sounds were
normal. His abdominal X-ray was suggestive of DIOS (Fig. 2),
however his CRP was 191 and WBC 25. An abdominal CT
was requested which showed pancolitis. He was treated empiri-
cally with intravenous metronidazole and oral vancomycin. The
Fig. 3. Flexible sigmoidoscopy showing yellow adherent plaques (white arrows)
typical of pseudomembranous colitis.
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C. difficile cytotoxin but a flexible sigmoidoscopy showed
pseudomembranous colitis (Fig. 3). Despite 2 days of intra-
venous antibiotics his CRP rose to 310. Intravenous hydro-
cortisone was started and 5 days later his CRP fell to 25. He
completed 7 days of intravenous metronidazole and 28 days
of oral vancomycin. The intravenous hydrocortisone was con-
verted to prednisolone and gradually weaned to zero.
Eight months later, having had two uneventful courses of
intravenous antibiotics for pulmonary exacerbations, he pre-
sented again with constipation, vomiting, high fevers and ab-
dominal pain. Immediately prior to this he had taken a two
week course of azithromycin 500 mg daily to treat a pulmo-
nary exacerbation. CT confirmed pancolitis with proximal small
bowel obstruction. This was resolved after 4 days of treatment
with intravenous metronidazole, oral vancomycin and intrave-
nous hydrocortisone. TOBI nebs were started as prophylaxis
in preference to oral agents and he was encouraged to take
probiotics.
4. Discussion
Positive stool cultures for C. difficile have been reported
in up to 43% of individuals with CF but patients with toxin
producing strains were asymptomatic [1] and overall the re-
ported incidence of symptomatic C. difficile infection is low
[2]. No individuals attending our CF centre had been diagnosed
with C. difficile colitis until 2006 and the cause of this apparent
cluster remains unclear. Following contact with the organism,
treatment with antibiotics is the major risk factor for the de-
velopment of C. difficile colonisation. Impaired immunity and
reduction of gastric acidity are also associated factors [3,4].
While none of the three patients had been in contact at any
time, all three had recently been prescribed intravenous anti-
pseudomonal antibiotics, intermittent courses of oral ciproflox-
acin, macrolides long term and proton pump inhibitors. Fluo-
roquinolone resistant C. difficile strains have been implicated
in severe nosocomial outbreaks of C. difficile diarrhoea [5] and
studies in the non-CF population suggest that macrolides area significant risk factor [6]. Genes encoding fluoroquinolone
and macrolide resistance in C. difficile have been identified and
may be becoming more prevalent [7]. As a consequence, we
have tended to stop macrolide prophylaxis in individuals that
have developed C. difficile colitis, unless the potential benefit of
continuation outweighs the theoretical risk, as in Case 2 where
clarithromycin was prescribed in the context of M. abscessus
infection.
The cases described are notable for the insidious onset of
symptoms, with little or no diarrhoea, culminating in the de-
velopment of fulminant C. difficile pancolitis. The absence of
diarrhoea is perhaps unsurprising given the pivotal role of CFTR
in chloride secretion into the intestinal lumen. The symptoms
and abdominal X-ray may, in fact, be suggestive of DIOS, as in
Case 3. It is therefore important to consider C. difficile colitis in
CF patients presenting with fevers and vague gastrointestinal
symptoms.
The recent report of four CF patients with fulminantC. difficile
colitis following lung transplantation with 50% mortality high-
lights the importance of vigilance for the presence of this patho-
gen [8]. A prior history of C. difficile colitis may now need to be
considered when assessing the suitability of individuals for lung
transplant listing.
While identification of C. difficile toxin in stool may indi-
cate the presence of disease, no test is 100% sensitive and
sigmoidoscopy may be required to confirm the diagnosis, as in
Case 3. This test is safe in patients with severe colonic inflam-
mation when performed by experienced operators [9]. Abdom-
inal CT scanning made a major contribution in securing the
diagnosis in our series and suggests that cross sectional imag-
ing is useful in narrowing the differential diagnosis in patients
presenting with non-specific abdominal pain in the context of
fevers and high inflammatory markers.
Oral metronidazole is the first line treatment for C. difficile
and intravenous metronidazole is also efficacious. If there
is no improvement in symptoms after 3 days, oral or rectal
vancomycin or oral teicoplanin may be added [10]. There is
some evidence to support the use of probiotics to promote
recolonisation with normal bowel flora [11]. Although there is
little evidence for the use of systemic steroids in patients with
pseudomembranous colitis, the close temporal relationship be-
tween the prescription of systemic steroids and clinical im-
provement, particularly in Cases 2 and 3 in our series, suggests
that they were beneficial.
Inability to mount an adequate specific antibody response to
C. difficile toxins predisposes patients to more severe disease
[3] and could predict those patients most at risk. Case series
report success in using C. difficile toxoid vaccine or intrave-
nous immunoglobulin for recurrent or refractory cases [12,13].
If symptoms were to recur despite cessation of oral antibiotic
prophylaxis and use of probiotics, one could consider prophy-
lactic immunoglobulin as in other forms of specific antibody
deficiency.
In summary, C. difficile colitis should be considered in CF
individuals presenting with non-specific abdominal symptoms.
Systemic steroids may be beneficial in patients with pancolitis
not responding to conventional antibiotic treatment.
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